CTTI’s Mobile Clinical Trials (MCT) Program focuses on integrating new mobile technologies in the design and conduct of clinical trials. Although medical research steadily progresses, the clinical trial enterprise can be slow to adopt new approaches and tools. As noted by Janet Woodcock in a recent article published by The Guardian, both pharmaceutical companies and regulators desire more innovation in the clinical trial setting. Aligned with this goal, the article recognized CTTI efforts to help increase innovation through initiating the MCT program. Dr. Martin Landray, a MCT Program leader and medical expert, was also quoted in the article, acknowledging that many currently used tests or metrics are outdated and do not provide the best information to guide patient treatment. He points out that wearable technology can provide more comprehensive data on a patient’s activities and health measurements. Additionally, according to The Guardian article, Landray

“estimates that in some cases, shifting to a mobile-based trial may reduce costs by 10-fold. This cost cutting, coupled with the fact that mobile trials’ recruitment efforts are not limited by geography, has the potential to advance our scientific understanding of rare diseases.”

CTTI is committed to helping the clinical trial enterprise explore the benefits offered by technological advancements with remote capabilities. The MCT Program seeks to address important issues related to the successful integration of mobile technologies in clinical trial conduct, including receptivity within the current legal/regulatory frameworks, stakeholder perceptions regarding risks and benefits of its use, and technical aspects of practical application.